Last C$1.39 CAD
Change Today 0.00 / 0.00%
Volume 0.0
RBM On Other Exchanges
Symbol
Exchange
Toronto
OTC BB
Stuttgart
Frankfurt
As of 9:37 AM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

response biomedical corp (RBM) Snapshot

Open
C$1.40
Previous Close
C$1.39
Day High
C$1.40
Day Low
C$1.39
52 Week High
08/20/13 - C$3.20
52 Week Low
11/19/13 - C$1.26
Market Cap
11.0M
Average Volume 10 Days
389.0
EPS TTM
C$-0.70
Shares Outstanding
7.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RESPONSE BIOMEDICAL CORP (RBM)

Related News

No related news articles were found.

response biomedical corp (RBM) Related Businessweek News

No Related Businessweek News Found

response biomedical corp (RBM) Details

Response Biomedical Corp. is engaged in the research, development, commercialization, and distribution of diagnostic technologies for the medical central-lab testing, point of care (POC) testing, and on-site environmental testing markets. The POC and on-site diagnostic tests are non-laboratory based tests performed using portable hand-held devices, compact desktop analyzers, single-use test cartridges, and/or dipsticks. It provides RAMP system, which is a portable fluorescence immunoassay-based diagnostic technology that combines the performance of a clinical lab with the convenience of a dipstick test. The company’s RAMP tests are used in the early detection of heart attack, congestive heart failure, influenza A+B, the respiratory syncytial virus, and environmental detection of West Nile Virus; and biodefense applications, including the rapid on-site detection of anthrax, smallpox, ricin, and botulinum toxin. Response Biomedical Corp. sells its products through distributors primarily in China, the United States, Asia, Europe, Canada, and internationally. The company was founded in 1980 and is headquartered in Vancouver, Canada.

65 Employees
Last Reported Date: 03/17/14
Founded in 1980

response biomedical corp (RBM) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: C$369.0K
Chief Financial Officer and Corporate Secreta...
Total Annual Compensation: C$241.5K
Corporate Controller
Total Annual Compensation: C$110.0K
Vice President of Research & Development
Total Annual Compensation: C$180.0K
Consultant
Total Annual Compensation: C$112.0K
Compensation as of Fiscal Year 2013.

response biomedical corp (RBM) Key Developments

Response Biomedical Corp. Presents at Bloom Burton & Co. Healthcare Investor Conference, Jun-18-2014 04:30 PM

Response Biomedical Corp. Presents at Bloom Burton & Co. Healthcare Investor Conference, Jun-18-2014 04:30 PM. Venue: Toronto Board of Trade, 1 First Canadian Place (Corner of Bay and Adelaide), Toronto, ON M5X 1C1, Canada. Speakers: Jeffrey L. Purvin, Chief Executive Officer, Director and Member of Option Committee.

Response Biomedical Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Response Biomedical reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. GAAP net loss for the quarter ended March 31, 2014 totaled CAD 1.52 million or CAD 0.19 per basic and diluted share, compared to a CAD 9.96 million GAAP net loss or CAD 1.53 per basic and diluted share, in the comparative 2013 period. The decrease in the loss was primarily due to a CAD 9.32 million decrease in the unrealized loss on revaluation of the warrant liability offset by the decrease in product sales and increase in operating expenses mentioned above. Adjusted net loss increased by CAD 0.97 million to CAD 1.36 million from the CAD 0.40 million adjusted net loss in the comparable quarter in 2013. Adjusted EBITDA for the quarter ended March 31, 2014 was negative CAD 0.80 million compared to positive CAD 0.15 million in the same quarter of 2013. Adjusted EBITDA excludes, for the applicable periods, interest expense, interest income, income tax, depreciation and amortization, stock-based compensation expense, and the non-cash unrealized loss on the revaluation of the warrant liability. Product sales were CAD 2.559 million against CAD 3.561 million a year ago.

Response Biomedical Corp. Appoints Jeffrey L. Purvin as Director

Response Biomedical Corp. announced at the AGM held on May 8, 2014 the shareholders appointed Jeffrey L. Purvin as director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RBM:CN C$1.39 CAD 0.00

RBM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $118.58 USD +0.09
Cepheid $40.14 USD -0.412
Quidel Corp $23.08 USD -0.47
Siemens AG €93.63 EUR -0.86
View Industry Companies
 

Industry Analysis

RBM

Industry Average

Valuation RBM Industry Range
Price/Earnings 4.2x
Price/Sales 1.1x
Price/Book NM Not Meaningful
Price/Cash Flow 4.7x
TEV/Sales 0.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESPONSE BIOMEDICAL CORP, please visit www.responsebio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.